Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion.

B7-H3 cell surface proteomics rhabdomyosarcoma targeted therapies

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
09 Sep 2021
Historique:
received: 29 06 2021
revised: 10 08 2021
accepted: 17 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Novel therapeutic strategies are needed for the treatment of rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. By using a combination of cell surface proteomics and transcriptomic profiling of RMS and normal muscle, we generated a catalog of targetable cell surface proteins enriched in RMS tumors. Among the top candidates, we identified B7-H3 as the major immunoregulatory molecule expressed by RMS tumors. By using a large cohort of tissue specimens, we demonstrated that B7-H3 is expressed in a majority of RMS tumors while not detected in normal human tissues. Through a deconvolution analysis of the RMS tumor RNA-seq data, we showed that B7-H3-rich tumors are enriched in macrophages M1, NK cells, and depleted in CD8

Identifiants

pubmed: 34572755
pii: cancers13184528
doi: 10.3390/cancers13184528
pmc: PMC8466404
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Med. 2020 May;26(5):712-719
pubmed: 32341579
Mol Med Rep. 2016 Apr;13(4):3190-6
pubmed: 26936314
Nat Biotechnol. 2009 Apr;27(4):378-86
pubmed: 19349973
Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482
pubmed: 29686080
Cancer Discov. 2014 Feb;4(2):216-31
pubmed: 24436047
Clin Cancer Res. 2021 Mar 1;27(5):1227-1235
pubmed: 33051306
Cancer Chemother Pharmacol. 2018 Feb;81(2):245-253
pubmed: 29299639
Cancer Res. 2008 Aug 15;68(16):6559-68
pubmed: 18701479
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Mol Cancer Ther. 2020 Nov;19(11):2235-2244
pubmed: 32967924
J Clin Oncol. 1995 Mar;13(3):610-30
pubmed: 7884423
Elife. 2018 Jan 23;7:
pubmed: 29359686
Pathol Res Pract. 2019 Dec;215(12):152700
pubmed: 31704149
ScientificWorldJournal. 2015;2015:137076
pubmed: 26665161
Sci Rep. 2020 Feb 12;10(1):2478
pubmed: 32051485
Nat Rev Drug Discov. 2014 Jan;13(1):39-62
pubmed: 24378802
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
Mol Cancer Ther. 2017 Jul;16(7):1203-1211
pubmed: 28679835
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
BMC Cancer. 2018 Jun 13;18(1):652
pubmed: 29898687
Cancer. 1988 Jan 15;61(2):209-20
pubmed: 3275486
Nat Genet. 1993 Feb;3(2):113-7
pubmed: 8098985
Oncol Rep. 2015 Jan;33(1):274-82
pubmed: 25370943
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7764-7775
pubmed: 32205440
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Genome Med. 2019 May 24;11(1):34
pubmed: 31126321
Sci Signal. 2011 May 31;4(175):pe28
pubmed: 21632467
Cancer Discov. 2021 Aug;11(8):2032-2049
pubmed: 33727310
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33483421
Development. 2012 Nov;139(22):4105-9
pubmed: 23093422
BMC Clin Pathol. 2014 Feb 04;14(1):8
pubmed: 24495444
Trends Cancer. 2018 Jun;4(6):401-404
pubmed: 29860983
JAMA. 2010 Jul 14;304(2):172-9
pubmed: 20628130
Int J Biol Sci. 2020 Mar 25;16(11):1767-1773
pubmed: 32398947
Eur J Cancer. 2020 Jul;133:74-85
pubmed: 32447027
Cell Res. 2017 Aug;27(8):1034-1045
pubmed: 28685773
Oncogene. 2018 Jul;37(27):3617-3630
pubmed: 29610525
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
Mol Syst Biol. 2016 Apr 04;12(4):862
pubmed: 27044256
Int J Mol Sci. 2019 Aug 18;20(16):
pubmed: 31426573
Nat Commun. 2020 Jul 15;11(1):3549
pubmed: 32669548
Cancer Res. 2010 Aug 15;70(16):6497-508
pubmed: 20663909
Pediatr Blood Cancer. 2005 Jun 15;44(7):643-53
pubmed: 15700252
Anal Chem. 2003 Sep 1;75(17):4646-58
pubmed: 14632076
Oncoimmunology. 2015 Mar 06;4(2):e977164
pubmed: 25949876
Cancer Res. 2006 Jul 15;66(14):6936-46
pubmed: 16849537
Nat Immunol. 2020 May;21(5):555-566
pubmed: 32327756
Nat Biotechnol. 2020 Feb;38(2):233-244
pubmed: 31907405
Cancer Res. 1994 Jun 1;54(11):2869-72
pubmed: 8187070
Cell. 2020 Oct 1;183(1):269-283.e19
pubmed: 32916130
Oncol Lett. 2017 Nov;14(5):6177-6183
pubmed: 29113264
Mol Cell. 2021 Mar 18;81(6):1170-1186.e10
pubmed: 33571422
Pediatr Blood Cancer. 2013 Sep;60(9):1411-7
pubmed: 23526739
Cell Death Dis. 2019 Jul 4;10(7):514
pubmed: 31273190
Cancer. 1993 Mar 1;71(5):1904-22
pubmed: 8448756

Auteurs

Roxane R Lavoie (RR)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Patricio C Gargollo (PC)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Mohamed E Ahmed (ME)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Yohan Kim (Y)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Emily Baer (E)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Doris A Phelps (DA)

Greehey Children's Cancer Research Institute, San Antonio, TX 78229, USA.

Cristine M Charlesworth (CM)

Proteomic Core, Mayo Clinic, Rochester, MN 55902, USA.

Benjamin J Madden (BJ)

Proteomic Core, Mayo Clinic, Rochester, MN 55902, USA.

Liguo Wang (L)

Division of Computational Biology, Mayo Clinic, Rochester, MN 55902, USA.

Peter J Houghton (PJ)

Greehey Children's Cancer Research Institute, San Antonio, TX 78229, USA.

John Cheville (J)

Department of Anatomic Pathology, Mayo Clinic, Rochester, MN 55902, USA.

Haidong Dong (H)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.
Department of Immunology, Mayo Clinic, Rochester, MN 55902, USA.

Candace F Granberg (CF)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Fabrice Lucien (F)

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Classifications MeSH